# Nanopath

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanopath

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.nanopathdx.com
- Total disclosed funding: $10M
- Latest round: Series A (Jun 14, 2022)
- Investors on record: 4

## About

Based in Massachusetts, US, and founded in 2019 by co-founders Dr. Amogha Tadimety and Dr. Alison Burklund, Nanopath Inc., aka Nanopath provider of a biosensing platform that diagnoses pelvic and gynecologic infections. Nanopath's technology enables testing for numerous diseases at the same time based on symptoms and delivers test results within 15 minutes. In June 2022, Nanopath Inc. raised USD 10 million in Series A funding, co-led by Norwest Venture Partners and SV Health Investors, Gingerbread Capital, and Green D Ventures.

The company's platform uses bioengineering and nanotechnology to detect viral, bacterial, and fungal diseases without the requirement for nucleic acid amplification, allowing doctors to enhance women's health by giving granular and clinically relevant information.

## Funding rounds

- Series A, Jun 14, 2022, $10M — Norwest Venture Partners, SV Health Investors, Alumni Ventures Group, GingerBread Capital

## Investors

- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- GingerBread Capital (https://capitalatlas.ai/funds/gingerbread-capital) — Series A